Pavan Bhargava

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6198875/publications.pdf

Version: 2024-02-01

56 papers	2,613 citations	218677 26 h-index	197818 49 g-index
62 all docs	62 docs citations	62 times ranked	4105 citing authors

#	Article	IF	Citations
1	Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science, 2018, 360, 449-453.	12.6	489
2	Optical coherence tomography reflects brain atrophy in multiple sclerosis: A fourâ€year study. Annals of Neurology, 2015, 78, 801-813.	5.3	304
3	Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain, 2014, 137, 2271-2286.	7.6	128
4	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology, 2016, 86, 382-390.	1.1	124
5	Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. Journal of Clinical Investigation, 2020, 130, 3467-3482.	8.2	109
6	Gut Microbiome and Multiple Sclerosis. Current Neurology and Neuroscience Reports, 2014, 14, 492.	4.2	106
7	Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. EBioMedicine, 2021, 73, 103636.	6.1	85
8	Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation. JCI Insight, 2017, 2, .	5.0	79
9	Disease-modifying therapies modulate retinal atrophy in multiple sclerosis. Neurology, 2017, 88, 525-532.	1.1	73
10	Improved Visualization of Cortical Lesions in Multiple Sclerosis Using 7T MP2RAGE. American Journal of Neuroradiology, 2018, 39, 459-466.	2.4	65
11	The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemporary Clinical Trials, 2014, 39, 288-293.	1.8	64
12	Automatic segmentation of microcystic macular edema in OCT. Biomedical Optics Express, 2015, 6, 155.	2.9	60
13	Lipidomic characterization of extracellular vesicles in human serum. Journal of Circulating Biomarkers, 2019, 8, 184945441987984.	1.3	56
14	Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. Annals of Clinical and Translational Neurology, 2018, 5, 1211-1221.	3.7	55
15	Dimethyl fumarate alters Bâ€cell memory and cytokine production in MS patients. Annals of Clinical and Translational Neurology, 2017, 4, 351-355.	3.7	54
16	Outer retinal changes following acute optic neuritis. Multiple Sclerosis Journal, 2016, 22, 362-372.	3.0	53
17	Metabolomics in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 451-460.	3.0	49
18	Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls. Multiple Sclerosis Journal, 2016, 22, 753-760.	3.0	49

#	Article	IF	Citations
19	Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement. Multiple Sclerosis and Related Disorders, 2019, 30, 136-140.	2.0	45
20	Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition. Brain, 2021, 144, 1396-1408.	7.6	44
21	Dimethyl fumarate treatment alters NK cell function in multiple sclerosis. European Journal of Immunology, 2018, 48, 380-383.	2.9	41
22	Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes. Annals of Clinical and Translational Neurology, 2019, 6, 33-45.	3.7	39
23	Synaptic and complement markers in extracellular vesicles in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 509-518.	3.0	38
24	Metabolomics in multiple sclerosis disease course and progression. Multiple Sclerosis Journal, 2020, 26, 591-598.	3.0	36
25	Applying an Open-Source Segmentation Algorithm to Different OCT Devices in Multiple Sclerosis Patients and Healthy Controls: Implications for Clinical Trials. Multiple Sclerosis International, 2015, 2015, 1-10.	0.8	35
26	Early complement genes are associated with visual system degeneration in multiple sclerosis. Brain, 2019, 142, 2722-2736.	7.6	30
27	Leptomeningeal inflammation in multiple sclerosis: Insights from animal and human studies. Multiple Sclerosis and Related Disorders, 2018, 26, 173-182.	2.0	29
28	Intermittent calorie restriction alters T cell subsets and metabolic markers in people with multiple sclerosis. EBioMedicine, 2022, 82, 104124.	6.1	29
29	Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism. Cell Reports Medicine, 2021, 2, 100424.	6.5	26
30	Altered Levels of Toll-Like Receptors in Circulating Extracellular Vesicles in Multiple Sclerosis. Cells, 2019, 8, 1058.	4.1	25
31	The expanding spectrum of aetiologies causing retinal microcystic macular change. Brain, 2013, 136, 3212-3214.	7.6	20
32	Serum ceramide levels are altered in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1506-1519.	3.0	20
33	Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases. Clinical Infectious Diseases, 2022, 74, 427-436.	5.8	15
34	Contribution of B cells to cortical damage in multiple sclerosis. Brain, 2022, 145, 3363-3373.	7.6	15
35	Combined registration and motion correction of longitudinal retinal OCT data. Proceedings of SPIE, 2016, 9784, .	0.8	13
36	Brief Report: Antiâ€“Calponin 3 Autoantibodies: A Newly Identified Specificity in Patients With SjÃ¶grenâ€™s Syndrome. Arthritis and Rheumatology, 2018, 70, 1610-1616.	5.6	13

#	Article	IF	Citations
37	Analysis of Agreement of Retinal-Layer Thickness Measures Derived from the Segmentation of Horizontal and Vertical Spectralis OCT Macular Scans. Current Eye Research, 2018, 43, 415-423.	1.5	12
38	1,25-Dihydroxyvitamin D3 impairs the differentiation of effector memory T cells in vitro in multiple sclerosis patients and healthy controls. Journal of Neuroimmunology, 2015, 279, 20-24.	2.3	9
39	Clinical Reasoning: An unusual cause of transverse myelitis?. Neurology, 2014, 82, e46-50.	1.1	8
40	Longitudinal graph-based segmentation of macular OCT using fundus alignment. Proceedings of SPIE, 2015, 9413, .	0.8	8
41	An update on the evidence base for peginterferon Î²1a in the treatment of relapsingâ€“remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2016, 9, 483-490.	3.5	7
42	Exercise leads to metabolic changes associated with improved strength and fatigue in people with MS. Annals of Clinical and Translational Neurology, 2021, 8, 1308-1317.	3.7	6
43	Familial Transient Global Amnesia. Mayo Clinic Proceedings, 2015, 90, 696-697.	3.0	5
44	Peptidylarginine Deiminase 2 Autoantibodies Are Linked to Less Severe Disease in Multiple Sclerosis and Post-treatment Lyme Disease. Frontiers in Neurology, 0, 13, .	2.4	5
45	A Pediatric Case of Painful Legs and Moving Toes Syndrome. Pediatric Neurology, 2013, 49, 298-299.	2.1	4
46	Right Brain: Humor completes the neurologic examination. Neurology, 2014, 82, e21-2.	1.1	4
47	A Unique Case of Intravascular Lymphoma Mimicking Encephalomyeloradiculoneuropathy. Neurologist, 2015, 20, 18-21.	0.7	4
48	Mitochondrial measures in neuronally enriched extracellular vesicles predict brain and retinal atrophy in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 2020-2026.	3.0	4
49	Targeting metabolism to treat multiple sclerosis. Neural Regeneration Research, 2021, 16, 502.	3.0	2
50	Osteoporosis in ankylosing spondylitis. International Journal of Rheumatic Diseases, 2008, 11, 374-380.	1.9	1
51	Survival in rhinocerebral mucormycosis: Is iron the key?. Neurology India, 2007, 55, 416.	0.4	1
52	Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies. Lancet Rheumatology, The, 2022, 4, e247.	3.9	1
53	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology, 2016, 87, 446-446.	1.1	0
54	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology, 2016, 87, 445-446.	1.1	0

#	Article	IF	Citations
55	Drug compliance after stroke and myocardial infarction: Is complementary medicine an issue?. Neurology India, 2008, 56, 93.	0.4	0
56	Response toâ€”Tracking the role of sphingolipids in MS: The dynamic nature of ceramide synthases. Multiple Sclerosis Journal, 2022, , 135245852210840.	3.0	0